ReviewLancet (London, England)2020
Intersection of biology and therapeutics: type 2 targeted therapeutics for adult asthma.
Review in Lancet (London, England), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 79 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
79 citing papers in PubMed, 1 synthesis or guideline pooled it, 148 citations in OpenAlex.
- The effectiveness of physical activity in asthma management: An overview of systematic reviews.PloS one · 2025Pooled it
- Elarekibep, an inhaled anti-IL-4 receptor alpha Anticalin, in moderate-to-severe asthma: a randomized, placebo-controlled phase 2a study (APATURA).Respiratory research · 2026Trial
- Profiling cellular heterogeneity in asthma with single cell multiparameter CyTOF.Journal of leukocyte biology · 2020Trial
- Article
- Impact of non-pharmacological adjuvant interventions on adult asthma patients: a systematic review and network meta-analysis.Journal of thoracic disease · 2026Article
- The Airway Epithelial Barrier in Childhood Asthma: A Central Player in Glucocorticoid Therapy, Resistance, and Severe Asthma.Pediatric discovery · 2026Review
- HuR Regulates GATA3-Driven Type 2 Inflammation in CD4bioRxiv : the preprint server for biology · 2026Article
- Lactobacillus rhamnosus regulates airway epithelial cell senescence through the ADCK5/PI3K/AKT signaling axis and alleviates airway inflammation in asthma.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Glucocorticoids injure the airway epithelial barrier via endoplasmic reticulum stress-related apoptosis in asthma.Frontiers in pharmacology · 2026Article
- Phenotyping moderate asthma earlier by analyzing induced sputum eosinophils, blood eosinophils, and atopy: a cross-sectional comparison with severe asthma.Respiratory research & clinical practice · 2026Article
- Clostridium leptum attenuates allergic airway inflammation via tDC‒Treg axis activation in a murine model of gut dysbiosis-associated asthma.Scientific reports · 2025Article
- Article
- Spatial Eosinophil Phenotypes as Immunopathogenic Determinants in Inflammatory Diseases.Cells · 2025Review
- Fecal Microbiota Transplantation Alleviates Airway Inflammation in Asthmatic Rats by Increasing the Level of Short-Chain Fatty Acids in the Intestine.Inflammation · 2025Article
- Effectiveness and safety of dupilumab in children with moderate-to-severe asthma in China: A retrospective real-world study.Chinese medical journal · 2025Article
- Pulmonary-delivered Anticalin Jagged-1 antagonists reduce experimental airway mucus hyperproduction and obstruction.American journal of physiology. Lung cellular and molecular physiology · 2025Article
- Ferroptosis-Related Gene CRYAB in Asthma: Bioinformatics Identification and Experimental Validation.Journal of inflammation research · 2025Article
- Tumor Necrotic Factor-Alpha (-308A/G, rs1800629) and Interleukin-13 (R130Q, rs20541) Gene Polymorphisms as Predictors of Severe Asthma in Pilot Cohort of Kuwaiti Population: Influence of Age, Nasal Polyps, Fractional Exhaled Nitric Oxide, and Blood Eosinophil Count.Journal of asthma and allergy · 2025Article
- Application of Biologics in the Treatment of Asthma in the Past Two Decades: A Bibliometric Analysis and Beyond.Journal of asthma and allergy · 2025Review
- Durability of benralizumab effectiveness in severe eosinophilic asthma patients with and without chronic rhinosinusitis with nasal polyps: aFrontiers in allergy · 2025Article
19 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Asthma is a disease of reversible airflow obstruction characterised clinically by wheezing, shortness of breath, and coughing. Increases in airway type 2 cytokine activity, including interleukin-4 (IL-4), IL-5, and IL-13, are now established biological mechanisms in asthma. Inhaled corticosteroids have been the foundation for asthma treatment, in a large part because they decrease airway type 2 inflammation. However, inhaled or systemic corticosteroids are ineffective treatments in many patients with asthma and few treatment options exist for patients with steroid resistant asthma. Although mechanisms for corticosteroid refractory asthma are likely to be numerous, the development of a new class of biologic agents that target airway type 2 inflammation has provided a new model for treating some patients with corticosteroid refractory asthma. The objective of this Therapeutic paper is to summarise the new type 2 therapeutics, with an emphasis on the biological rationale and clinical efficacy of this new class of asthma therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.